JP2015514794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514794A5 JP2015514794A5 JP2015507544A JP2015507544A JP2015514794A5 JP 2015514794 A5 JP2015514794 A5 JP 2015514794A5 JP 2015507544 A JP2015507544 A JP 2015507544A JP 2015507544 A JP2015507544 A JP 2015507544A JP 2015514794 A5 JP2015514794 A5 JP 2015514794A5
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- benzenesulfonamide
- dimethylisoxazol
- isobutyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 10
- -1 CF 3 Chemical group 0.000 claims 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000003566 oxetanyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- MBJFVCXMWMSSLW-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)-n-(5-methylpyridin-2-yl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C)C=N1 MBJFVCXMWMSSLW-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- BITYBNILXJZPJP-UHFFFAOYSA-N 2-chloro-n-(3,5-dimethylpyridin-2-yl)-n-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide Chemical compound C=1C=C(OCC2CCOCC2)C=C(Cl)C=1S(=O)(=O)N(CC(C)C)C1=NC=C(C)C=C1C BITYBNILXJZPJP-UHFFFAOYSA-N 0.000 claims 1
- XIIBUQNVEZIGQW-UHFFFAOYSA-N 4-(1-hydroxy-2-morpholin-4-ylethyl)-n-(2-methylpropyl)-n-(5-propan-2-ylpyridin-2-yl)benzenesulfonamide Chemical compound C=1C=C(C(O)CN2CCOCC2)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(C)C)C=N1 XIIBUQNVEZIGQW-UHFFFAOYSA-N 0.000 claims 1
- KHKUGENBMBXNIQ-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2,6-dimethylpyridin-3-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C)N=C1C KHKUGENBMBXNIQ-UHFFFAOYSA-N 0.000 claims 1
- FEKXJMYTNGIYKG-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylbutyl)-n-(5-propan-2-ylpyridin-2-yl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)CC)C1=CC=C(C(C)C)C=N1 FEKXJMYTNGIYKG-UHFFFAOYSA-N 0.000 claims 1
- YKDOMQASMPFPKM-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)-n-(2-methyl-6-pyrrolidin-3-ylpyridin-3-yl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C(C(=N1)C)=CC=C1C1CCNC1 YKDOMQASMPFPKM-UHFFFAOYSA-N 0.000 claims 1
- CEBTYGUMWZZEAP-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)-n-(5-propan-2-ylpyridin-2-yl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(C)C)C=N1 CEBTYGUMWZZEAP-UHFFFAOYSA-N 0.000 claims 1
- KQUMQBLGKIKAKZ-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)-n-[2-(trifluoromethyl)pyrimidin-4-yl]benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=NC(C(F)(F)F)=N1 KQUMQBLGKIKAKZ-UHFFFAOYSA-N 0.000 claims 1
- MKZZICXSCAGTHZ-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)-n-[4-(trifluoromethyl)pyrimidin-2-yl]benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=CC(C(F)(F)F)=N1 MKZZICXSCAGTHZ-UHFFFAOYSA-N 0.000 claims 1
- ZDGOVPCGLCSEIV-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(3,5-dimethylpyrazin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=C(C)N=C1C ZDGOVPCGLCSEIV-UHFFFAOYSA-N 0.000 claims 1
- CKQXPDNKLSSMAX-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(3,5-dimethylpyridin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=C(C)C=C1C CKQXPDNKLSSMAX-UHFFFAOYSA-N 0.000 claims 1
- XEIRXJFXSZRLLQ-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(3,6-dimethylpyrazin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC(C)=CN=C1C XEIRXJFXSZRLLQ-UHFFFAOYSA-N 0.000 claims 1
- YSBUPVYCWKAIGO-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(3-ethyl-6-methylpyridin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound CCC1=CC=C(C)N=C1N(CC(C)C)S(=O)(=O)C(C=C1)=CC=C1OCC1=C(C)ON=C1C YSBUPVYCWKAIGO-UHFFFAOYSA-N 0.000 claims 1
- NCGIRCPQOFDVTF-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(3-methylbutyl)-n-(5-propan-2-ylpyridin-2-yl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CCC(C)C)C1=CC=C(C(C)C)C=N1 NCGIRCPQOFDVTF-UHFFFAOYSA-N 0.000 claims 1
- YQLJZMREPNRHKG-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(4,6-dimethylpyridin-3-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=CN=C(C)C=C1C YQLJZMREPNRHKG-UHFFFAOYSA-N 0.000 claims 1
- LDVXYMLZEPGZDA-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(4,6-dimethylpyrimidin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC(C)=CC(C)=N1 LDVXYMLZEPGZDA-UHFFFAOYSA-N 0.000 claims 1
- NVUFTOOTFXKGBC-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(5-ethylpyrimidin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound N1=CC(CC)=CN=C1N(CC(C)C)S(=O)(=O)C(C=C1)=CC=C1OCC1=C(C)ON=C1C NVUFTOOTFXKGBC-UHFFFAOYSA-N 0.000 claims 1
- XMWZFLDYXGZLQR-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(5-fluoropyridin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(F)C=N1 XMWZFLDYXGZLQR-UHFFFAOYSA-N 0.000 claims 1
- NIWJYSZVQOPCBP-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(6-ethoxypyridazin-3-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound N1=NC(OCC)=CC=C1N(CC(C)C)S(=O)(=O)C(C=C1)=CC=C1OCC1=C(C)ON=C1C NIWJYSZVQOPCBP-UHFFFAOYSA-N 0.000 claims 1
- NSRQEEGXPBSGTM-UHFFFAOYSA-N 4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(6-methoxypyridazin-3-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound N1=NC(OC)=CC=C1N(CC(C)C)S(=O)(=O)C(C=C1)=CC=C1OCC1=C(C)ON=C1C NSRQEEGXPBSGTM-UHFFFAOYSA-N 0.000 claims 1
- PKQWGKIJTTVJBZ-HYBUGGRVSA-N 4-[[(3s,4r)-3-fluoropiperidin-4-yl]methoxy]-n-(3-methyl-5-propan-2-ylpyridin-2-yl)-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OC[C@@H]2[C@@H](CNCC2)F)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=C(C(C)C)C=C1C PKQWGKIJTTVJBZ-HYBUGGRVSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- ZTCCNJAVWUEBJC-UHFFFAOYSA-N n-(2-cyclopropylpyrimidin-5-yl)-4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C(C=N1)=CN=C1C1CC1 ZTCCNJAVWUEBJC-UHFFFAOYSA-N 0.000 claims 1
- ODTOSIJBXMJBRZ-UHFFFAOYSA-N n-(2-methylpropyl)-4-(oxan-4-ylmethoxy)-n-(5-propan-2-ylpyridin-2-yl)benzenesulfonamide Chemical compound C=1C=C(OCC2CCOCC2)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(C(C)C)C=N1 ODTOSIJBXMJBRZ-UHFFFAOYSA-N 0.000 claims 1
- LWEACDNFKYDAKP-UHFFFAOYSA-N n-(3,5-dimethylpyridin-2-yl)-n-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide Chemical compound C=1C=C(OCC2CCOCC2)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=C(C)C=C1C LWEACDNFKYDAKP-UHFFFAOYSA-N 0.000 claims 1
- LROWSBKQWVBMLW-UHFFFAOYSA-N n-(3-methoxy-5-propan-2-ylpyridin-2-yl)-n-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide Chemical compound COC1=CC(C(C)C)=CN=C1N(CC(C)C)S(=O)(=O)C(C=C1)=CC=C1OCC1CCOCC1 LROWSBKQWVBMLW-UHFFFAOYSA-N 0.000 claims 1
- AQRJWCFCXLPNTG-UHFFFAOYSA-N n-(3-methyl-5-prop-1-en-2-ylpyridin-2-yl)-n-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide Chemical compound C=1C=C(OCC2CCOCC2)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=C(C(C)=C)C=C1C AQRJWCFCXLPNTG-UHFFFAOYSA-N 0.000 claims 1
- LPEMIRPOQNTOOZ-UHFFFAOYSA-N n-(3-methyl-5-propan-2-ylpyridin-2-yl)-n-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide Chemical compound C=1C=C(OCC2CCOCC2)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=C(C(C)C)C=C1C LPEMIRPOQNTOOZ-UHFFFAOYSA-N 0.000 claims 1
- MHVBWCHVZNJXOJ-UHFFFAOYSA-N n-(3-methylbutan-2-yl)-4-(oxan-4-ylmethoxy)-n-(5-propan-2-ylpyridin-2-yl)benzenesulfonamide Chemical compound C=1C=C(OCC2CCOCC2)C=CC=1S(=O)(=O)N(C(C)C(C)C)C1=CC=C(C(C)C)C=N1 MHVBWCHVZNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- IKCDGWIVGDKKFV-UHFFFAOYSA-N n-(5-chloro-3-methylpyridin-2-yl)-n-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide Chemical compound C=1C=C(OCC2CCOCC2)C=CC=1S(=O)(=O)N(CC(C)C)C1=NC=C(Cl)C=C1C IKCDGWIVGDKKFV-UHFFFAOYSA-N 0.000 claims 1
- ZSUGXLBCMSKAHG-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C1=CC=C(Cl)C=N1 ZSUGXLBCMSKAHG-UHFFFAOYSA-N 0.000 claims 1
- ALVZFNUESAMNRF-UHFFFAOYSA-N n-(6-cyclopropylpyridazin-3-yl)-4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(OCC2=C(ON=C2C)C)C=CC=1S(=O)(=O)N(CC(C)C)C(N=N1)=CC=C1C1CC1 ALVZFNUESAMNRF-UHFFFAOYSA-N 0.000 claims 1
- VUYOURVRRXKCDI-UHFFFAOYSA-N n-(6-methoxypyridin-2-yl)-n-(2-methylpropyl)-4-(pyridin-4-ylmethoxy)benzenesulfonamide Chemical compound COC1=CC=CC(N(CC(C)C)S(=O)(=O)C=2C=CC(OCC=3C=CN=CC=3)=CC=2)=N1 VUYOURVRRXKCDI-UHFFFAOYSA-N 0.000 claims 1
- XZRSNLVAVQFMLA-UHFFFAOYSA-N n-(cyclobutylmethyl)-4-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-n-(5-propan-2-ylpyridin-2-yl)benzenesulfonamide Chemical compound N1=CC(C(C)C)=CC=C1N(S(=O)(=O)C=1C=CC(OCC2=C(ON=C2C)C)=CC=1)CC1CCC1 XZRSNLVAVQFMLA-UHFFFAOYSA-N 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 0 *c(cc1)c(C*=C)cc1S(N(*)*)(=O)=O Chemical compound *c(cc1)c(C*=C)cc1S(N(*)*)(=O)=O 0.000 description 8
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1207406.8A GB201207406D0 (en) | 2012-04-27 | 2012-04-27 | Novel compounds |
| GB1207406.8 | 2012-04-27 | ||
| PCT/EP2013/058667 WO2013160419A1 (en) | 2012-04-27 | 2013-04-25 | Novel compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514794A JP2015514794A (ja) | 2015-05-21 |
| JP2015514794A5 true JP2015514794A5 (enExample) | 2016-06-09 |
| JP6180509B2 JP6180509B2 (ja) | 2017-08-16 |
Family
ID=46330458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507544A Expired - Fee Related JP6180509B2 (ja) | 2012-04-27 | 2013-04-25 | 新規化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9242972B2 (enExample) |
| EP (1) | EP2841430A1 (enExample) |
| JP (1) | JP6180509B2 (enExample) |
| GB (1) | GB201207406D0 (enExample) |
| WO (1) | WO2013160419A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2871534A1 (en) | 2012-04-27 | 2013-10-31 | Glaxo Group Limited | Novel compounds |
| HRP20170638T1 (hr) | 2012-12-06 | 2017-06-30 | Glaxo Group Limited | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI |
| CN104530014B (zh) * | 2013-12-25 | 2018-03-20 | 中国科学院广州生物医药与健康研究院 | 2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 |
| SI3102576T1 (sl) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals, Llc | Inhibitorji dihidropirolopiridina ROR-gama |
| CA2950220A1 (en) | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| US9902735B2 (en) | 2014-05-28 | 2018-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl substituted compounds as RORγ inhibitors |
| PE20170137A1 (es) | 2014-05-28 | 2017-03-05 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos |
| BR112017007460A2 (pt) | 2014-10-14 | 2017-12-19 | Vitae Pharmaceuticals Inc | inibidores de di-hidropirrolopiridina de ror-gama |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| WO2017087608A1 (en) | 2015-11-20 | 2017-05-26 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| TWI691486B (zh) * | 2016-01-29 | 2020-04-21 | 日商東麗股份有限公司 | 環狀胺衍生物及其醫藥用途 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| FR3063079B1 (fr) | 2017-02-17 | 2019-03-22 | Galderma Research & Development | Derives sulfonamides hydroxyles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
| FR3065000A1 (fr) | 2017-04-06 | 2018-10-12 | Galderma Research & Development | Derives pyrazoles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| KR20200053481A (ko) | 2017-07-24 | 2020-05-18 | 비타이 파마슈티컬즈, 엘엘씨 | RORγ의 억제제 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN110913859A (zh) * | 2017-07-27 | 2020-03-24 | 东丽株式会社 | 圆形脱毛症的治疗剂或预防剂 |
| JPWO2019022234A1 (ja) * | 2017-07-27 | 2020-05-28 | 東レ株式会社 | 炎症性腸疾患の治療剤又は予防剤 |
| CN110945002B (zh) | 2017-08-01 | 2021-12-24 | 正大天晴药业集团股份有限公司 | 作为RORγ抑制剂的双环化合物 |
| EP3689860A4 (en) | 2017-09-30 | 2021-06-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS ROR INHIBITOR |
| EP3752510B1 (en) | 2018-02-15 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| EP4225748A1 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| PT83094B (pt) | 1985-07-30 | 1993-07-30 | Glaxo Group Ltd | Dispositivos proprios para a administracao de medicamentos a pacientes |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| RU2312854C2 (ru) | 2001-09-14 | 2007-12-20 | Глаксо Груп Лимитед | Производные фенэтаноламина для лечения респираторных заболеваний |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| GB201116641D0 (en) * | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
-
2012
- 2012-04-27 GB GBGB1207406.8A patent/GB201207406D0/en not_active Ceased
-
2013
- 2013-04-25 US US14/394,113 patent/US9242972B2/en not_active Expired - Fee Related
- 2013-04-25 JP JP2015507544A patent/JP6180509B2/ja not_active Expired - Fee Related
- 2013-04-25 WO PCT/EP2013/058667 patent/WO2013160419A1/en not_active Ceased
- 2013-04-25 EP EP13720869.0A patent/EP2841430A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514794A5 (enExample) | ||
| JP2021504443A5 (enExample) | ||
| JP6180509B2 (ja) | 新規化合物 | |
| JP2018534326A5 (enExample) | ||
| IL292488B2 (en) | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2018519323A5 (enExample) | ||
| JP2016516724A5 (enExample) | ||
| JP2016532673A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2007501264A5 (enExample) | ||
| JP2016519680A5 (enExample) | ||
| ME01308B (me) | Jedinjenja biaril etra uree | |
| RU2018138050A (ru) | Производные тиазолопиридина как агонисты gpr119 | |
| CA2982267C (en) | Novel dgat2 inhibitors | |
| CA2418868A1 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
| JP2018503673A5 (enExample) | ||
| JP2014523851A5 (enExample) | ||
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2017523215A5 (enExample) | ||
| JP2019505595A5 (enExample) | ||
| HRP20160635T1 (hr) | Inhibitori pirimidina pde10 | |
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
| RU2013130925A (ru) | Оксимовые соединения в качестве средств для повышения уровня холестерина высокой плотности |